NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.
Event: Q3 Investor Summit
Date: August 20th, 2024
Presentation Time: 2:00 pm ET
Location: https://www.webcaster4.com/Webcast/Page/3062/51117
The theme is 50 micro-cap companies with a catalyst and/or strong performance in the current market.
Take a deep dive with the best Investors in MicroCap
Live Q & A
Complimentary to Qualified Investors. Please REGISTER HERE.
The Investor Summit is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. Founded in 2015.
Contact:
Fred Rockwell
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Summit GroupSOURCE: Lixte Biotechnology Holdings, Inc.
| Last Trade: | US$2.06 |
| Daily Change: | -0.09 -4.19 |
| Daily Volume: | 12,242 |
| Market Cap: | US$4.640M |
August 15, 2024 June 14, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
